Literature DB >> 1562762

Thrombin-antithrombin III complexes in type II diabetes mellitus.

G Davì1, F Gennaro, A Spatola, I Catalano, M Averna, G Montalto, S Amato, A Notarbartolo.   

Abstract

Several studies suggest that diabetes is associated with a hypercoagulable state. Therefore determination of thrombin-antithrombin complex (TAT) could represent a sensitive parameter for specific detection of a latent activation of the clotting system. The present study documents increased plasma TAT in a heterogeneous group of non-insulin-dependent diabetic patients. The finding of increased TAT levels both in diabetic patients with vascular complications and in vascular disease patients without diabetes suggests a relationship between existing vascular disease and the hemostatic mechanism that produces augmented thrombin activity. In acute vascular occlusions the presence of diabetes seems to increase activation of the coagulative system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1562762     DOI: 10.1016/1056-8727(92)90042-j

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  7 in total

Review 1.  A risk-benefit assessment of abciximab in angioplasty.

Authors:  N S Kleiman
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 2.  Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus.

Authors:  Serdar Farhan; Thomas Höchtl; Alexandra Kautzky-Willer; Johann Wojta; Kurt Huber
Journal:  Wien Med Wochenschr       Date:  2010-01

Review 3.  The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.

Authors:  Michael S Lee; Andreas U Wali; Venu Menon; Scott D Berkowitz; Trevor D Thompson; Robert M Califf; Eric J Topol; Christopher B Granger; Judith S Hochman
Journal:  J Thromb Thrombolysis       Date:  2002-10       Impact factor: 2.300

Review 4.  Metabolic syndrome as a risk factor for neurological disorders.

Authors:  Akhlaq A Farooqui; Tahira Farooqui; Francesco Panza; Vincenza Frisardi
Journal:  Cell Mol Life Sci       Date:  2011-10-15       Impact factor: 9.261

5.  Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism.

Authors:  William Hinton; Banne Nemeth; Simon de Lusignan; Ben Field; Michael D Feher; Neil Munro; Lara N Roberts; Roopen Arya; Martin B Whyte
Journal:  Diabet Med       Date:  2020-11-27       Impact factor: 4.359

6.  Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.

Authors:  Doo Sun Sim; Myung Ho Jeong; Weon Kim; Jay Young Rhew; Ju Hyup Yum; Ju Han Kim; Jeong Gwan Cho; Young Keun Ahn; Jong Chun Park; Byoung Hee Ahn; Sang Hyung Kim; Jung Chaee Kang
Journal:  Korean J Intern Med       Date:  2003-09       Impact factor: 2.884

Review 7.  Coagulatory Defects in Type-1 and Type-2 Diabetes.

Authors:  Amélie I S Sobczak; Alan J Stewart
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.